John Michael Gaziano1, John Concato2, Mary Brophy3, Louis Fiore3, Saiju Pyarajan4, James Breeling4, Stacey Whitbourne4, Jennifer Deen4, Colleen Shannon4, Donald Humphries4, Peter Guarino5, Mihaela Aslan5, Daniel Anderson6, Rene LaFleur6, Timothy Hammond7, Kendra Schaa7, Jennifer Moser7, Grant Huang7, Sumitra Muralidhar7, Ronald Przygodzki7, Timothy J O'Leary7. 1. Massachusetts Area Veterans Epidemiology Research and Information Center (MAVERIC), VA Cooperative Studies Program, VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130, USA; Department of Internal Medicine, Harvard Medical School, Boston, MA, USA. 2. Clinical Epidemiology Research Center (CERC), VA Cooperative Studies Program, VA Connecticut Healthcare System, 950 Campbell Avenue, 151B, West Haven, CT 06516, USA; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. Electronic address: john.concato@va.gov. 3. Massachusetts Area Veterans Epidemiology Research and Information Center (MAVERIC), VA Cooperative Studies Program, VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130, USA; Department of Internal Medicine, Boston University School of Medicine, Boston, MA, USA. 4. Massachusetts Area Veterans Epidemiology Research and Information Center (MAVERIC), VA Cooperative Studies Program, VA Boston Healthcare System, 150 S. Huntington Avenue, Boston, MA 02130, USA. 5. Clinical Epidemiology Research Center (CERC), VA Cooperative Studies Program, VA Connecticut Healthcare System, 950 Campbell Avenue, 151B, West Haven, CT 06516, USA; Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA. 6. Clinical Epidemiology Research Center (CERC), VA Cooperative Studies Program, VA Connecticut Healthcare System, 950 Campbell Avenue, 151B, West Haven, CT 06516, USA. 7. Office of Research and Development, Veterans Health Administration, 810 Vermont Avenue N.W., 10P9, Washington, DC 20420, USA.
Abstract
OBJECTIVE: To describe the design and ongoing conduct of the Million Veteran Program (MVP), as an observational cohort study and mega-biobank in the Department of Veterans Affairs (VA) health care system. STUDY DESIGN AND SETTING: Data are being collected from participants using questionnaires, the VA electronic health record, and a blood sample for genomic and other testing. Several ongoing projects are linked to MVP, both as peer-reviewed research studies and as activities to help develop an infrastructure for future, broad-based research uses. RESULTS: Formal planning for MVP commenced in 2009; the protocol was approved in 2010, and enrollment began in 2011. As of August 3, 2015, and with a steady state of ≈50 recruiting sites nationwide, N = 397,104 veterans have been enrolled. Among N = 199,348 with currently available genotyping data, most participants (as expected) are male (92.0%) between the ages of 50 and 69 years (55.0%). On the basis of self-reported race, white (77.2%) and African American (13.5%) populations are well represented. CONCLUSIONS: By helping to promote the future integration of genetic testing in health care delivery, including clinical decision making, the MVP is designed to contribute to the development of precision medicine. Published by Elsevier Inc.
OBJECTIVE: To describe the design and ongoing conduct of the Million Veteran Program (MVP), as an observational cohort study and mega-biobank in the Department of Veterans Affairs (VA) health care system. STUDY DESIGN AND SETTING: Data are being collected from participants using questionnaires, the VA electronic health record, and a blood sample for genomic and other testing. Several ongoing projects are linked to MVP, both as peer-reviewed research studies and as activities to help develop an infrastructure for future, broad-based research uses. RESULTS: Formal planning for MVP commenced in 2009; the protocol was approved in 2010, and enrollment began in 2011. As of August 3, 2015, and with a steady state of ≈50 recruiting sites nationwide, N = 397,104 veterans have been enrolled. Among N = 199,348 with currently available genotyping data, most participants (as expected) are male (92.0%) between the ages of 50 and 69 years (55.0%). On the basis of self-reported race, white (77.2%) and African American (13.5%) populations are well represented. CONCLUSIONS: By helping to promote the future integration of genetic testing in health care delivery, including clinical decision making, the MVP is designed to contribute to the development of precision medicine. Published by Elsevier Inc.
Authors: Katherine P Liao; Jiehuan Sun; Tianrun A Cai; Nicholas Link; Chuan Hong; Jie Huang; Jennifer E Huffman; Jessica Gronsbell; Yichi Zhang; Yuk-Lam Ho; Victor Castro; Vivian Gainer; Shawn N Murphy; Christopher J O'Donnell; J Michael Gaziano; Kelly Cho; Peter Szolovits; Isaac S Kohane; Sheng Yu; Tianxi Cai Journal: J Am Med Inform Assoc Date: 2019-11-01 Impact factor: 4.497
Authors: Christopher A German; Janet S Sinsheimer; Yann C Klimentidis; Hua Zhou; Jin J Zhou Journal: Genet Epidemiol Date: 2019-12-26 Impact factor: 2.135
Authors: Akinyemi Oni-Orisan; Thomas J Hoffmann; Dilrini Ranatunga; Marisa W Medina; Eric Jorgenson; Catherine Schaefer; Ronald M Krauss; Carlos Iribarren; Neil Risch Journal: Circ Genom Precis Med Date: 2018-09
Authors: Yuelong Guo; Michael P Busch; Mark Seielstad; Stacy Endres-Dighe; Connie M Westhoff; Brendan Keating; Carolyn Hoppe; Aarash Bordbar; Brian Custer; Adam S Butterworth; Tamir Kanias; Alan E Mast; Steve Kleinman; Yontao Lu; Grier P Page Journal: Transfusion Date: 2018-11-20 Impact factor: 3.157
Authors: Kathleen A McGinnis; Amy C Justice; Janet P Tate; Henry R Kranzler; Hilary A Tindle; William C Becker; John Concato; Joel Gelernter; Boyang Li; Xinyu Zhang; Hongyu Zhao; Kristina Crothers; Ke Xu Journal: Addict Biol Date: 2018-10-04 Impact factor: 4.280